表紙:バイオマーカーの世界市場
市場調査レポート
商品コード
997311

バイオマーカーの世界市場

The World Market for Diagnostic Biomarkers (Tumor, Cardiac, Infectious Disease, AutoImmune, Others)

出版日: | 発行: Kalorama Information | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.49円
バイオマーカーの世界市場
出版日: 2021年04月08日
発行: Kalorama Information
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のバイオマーカー市場の構造と展望について分析し、市場の基本構造や背景事情、全体的な市場規模の動向見通し (2015年~2025年、基準年:2020年)、用途別 (臨床診断・研究など)・地域別の詳細動向とシェア構造、各種疾患向けバイオマーカーの市場動向、主な市場促進・抑制要因、主要企業のプロファイルや競合情勢などを調査しております。

目次

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 市場環境と分析

  • 概要
  • 一般的な動向
    • 人口構造パターン
    • マクロ経済予測
    • 医療環境
  • バイオマーカーの製品区分:世界の販売・市場動向
    • 感染症
    • がん
    • 心血管疾患
    • コアラボ
    • 神経疾患
    • 自己免疫疾患・関連症状
    • その他のバイオマーカー製品
  • バイオマーカー技術
    • 検査室イムノアッセイ
    • 分子技術
    • 迅速検査技術
    • その他の技術
  • 世界のバイオマーカー市場
    • 米国
    • カナダ・メキシコ
    • 西欧
    • 東欧
    • 中国
    • 日本
    • 他のアジア太平洋諸国
    • 中南米
    • 中東
    • アフリカ

第4章 感染症のバイオマーカー

  • 概要
  • 新型コロナウイルス感染症 (COVID-19) のバイオマーカー
  • 呼吸器感染症のバイオマーカー
    • 肺炎
    • インフルエンザ
    • A群連鎖球菌 (GAS) 感染症
    • 結核
    • その他の呼吸器感染症
  • 医療関連感染バイオマーカー
    • クロストリジオイデス・ディフィシル(旧称:クロストリジウム・ディフィシル)
    • 敗血症
    • 黄色ブドウ球菌(MRSAを含む)
    • 腸球菌(VREを含む)
  • 肝炎バイオマーカー
    • C型肝炎
    • A型肝炎
    • B型肝炎
    • その他の肝炎バイオマーカー
  • HIVバイオマーカー
  • HIV-
  • HIV-
  • 性感染症(STD)バイオマーカー
    • 単純ヘルペスウイルス(HSV)
    • ヒトパピローマウイルス(HPV-1/HPV-2)
    • トリコモナス症
    • クラミジア・淋病
    • その他のSTDバイオマーカー
  • TORCHバイオマーカー
  • その他の感染症バイオマーカー
    • マラリア
    • ライム病
    • 大腸菌(E. Coli)
    • ヘリコバクターピロリ(H. pylori)
    • その他の寄生虫病
    • その他の真菌性疾患
    • 他のすべての感染症バイオマーカー

第5章 がんバイオマーカー

  • 概要
  • 乳がんのバイオマーカー
  • 肺がんバイオマーカー
  • 前立腺がんのバイオマーカー
  • 結腸直腸がんのバイオマーカー
  • 黒色腫がんのバイオマーカー
  • 膀胱がんのバイオマーカー
  • 子宮がんバイオマーカー
  • 非ホジキンリンパ腫がんのバイオマーカー
  • 腎臓がんのバイオマーカー
  • 白血病のバイオマーカー
  • 膵臓がんのバイオマーカー
  • 甲状腺がんのバイオマーカー
  • 肝臓がんのバイオマーカー
  • 骨髄腫がんのバイオマーカー
  • 胃がんのバイオマーカー
  • 卵巣がんのバイオマーカー
  • 食道がんのバイオマーカー
  • 他のすべてのがんバイオマーカー

第6章 心血管疾患のバイオマーカー

  • 概要
  • 凝固/血栓溶解のバイオマーカー
  • コレステロール/脂質バイオマーカー
  • 冠状動脈疾患(CAD)バイオマーカー
  • アテローム性動脈硬化症のバイオマーカー
  • 脳血管のバイオマーカー
  • 心筋梗塞のバイオマーカー
  • その他の心血管疾患のバイオマーカー

第7章 コアラボ用バイオマーカー

  • 概要
  • グルコース
  • 電解質
  • 酵素
  • 糖化ヘモグロビン (HBA)
  • タンパク質
  • 乱用薬物
  • 治療薬
  • 他のすべてのコアラボ用バイオマーカー

第8章 神経疾患バイオマーカー

  • 概要
  • アルツハイマー病のバイオマーカー
  • その他の認知症のバイオマーカー
  • 精神疾患のバイオマーカー
  • 多発性硬化症のバイオマーカー
  • パーキンソン病のバイオマーカー
  • その他の神経疾患のバイオマーカー

第9章 自己免疫疾患・関連症状のバイオマーカー

  • 概要
  • 橋本病の甲状腺炎バイオマーカー
  • 潰瘍性大腸炎のバイオマーカー
  • 関節リウマチのバイオマーカー
  • 全身性エリテマトーデス(SLE)バイオマーカー
  • タイプ
  • 糖尿病のバイオマーカー
  • セリアック病のバイオマーカー
  • クローン病のバイオマーカー
  • 他のすべての自己免疫疾患・関連症状のバイオマーカー

第10章 その他のバイオマーカー

  • 概要
  • タイプ
  • 糖尿病・その他の代謝性疾患のバイオマーカー
  • 生殖能力・妊娠のバイオマーカー
  • 腎臓病のバイオマーカー
  • 遺伝性疾患のバイオマーカー
  • 甲状腺疾患のバイオマーカー
  • その他のバイオマーカー

第11章 企業プロファイル

  • 20/20 GeneSystems, Inc.
  • Abacus Diagnostica Oy
  • Abbott Laboratories
  • Act Genomics Co., Ltd.
  • Adaptive Biotechnologies Corp.
  • Admera Health
  • Agena Bioscience Inc.
  • Agendia NV
  • Agilent Technologies, Inc.
  • ALPCO
  • Ambry Genetics Corp.
  • Athena Diagnostics, Inc. /Quest
  • Banyan Biomarkers, Inc.
  • Beckman Coulter, Inc./Danaher Corp.
  • Becton, Dickinson and Company
  • BioFire Diagnostics, LLC/BioMerieux
  • Biohit Oyj
  • bioMErieux SA
  • Bio-Rad Laboratories, Inc.
  • Cancer Genetics, Inc.
  • Caris Life Sciences
  • Cepheid/Danaher Corp.
  • Curetis AG
  • Exact Sciences Corp.
  • Foundation Medicine, Inc.
  • Fujirebio, Inc.
  • Genomic Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics
  • NeoGenomics
  • Ortho-Clinical Diagnostics
  • Qiagen N.V.
  • Roche
  • Siemens Healthineers
  • Sysmex Corp.
  • Thermo Fisher Scientific, Inc.
  • Ventana Medical Systems, Inc./Roche
  • Zeus Scientific, Inc.
目次
Product Code: 21-017c

Biomarkers are biological or biochemical molecules, genetic changes, or other characteristics that can be measured; they indicate or predict a condition, risk, or likely biological response. Biomarkers can be used for a range of diagnostic applications including diagnosis, predicting prognosis, identifying appropriate therapy for an individual, monitoring disease or for return of a disease, and other applications.

This report focuses on diagnostics. The World Market for Biomarkers estimates the world markets for biomarkers and biomarker tests from 2015 to 2024, with 2020 as the base year, providing global biomarker market forecasts for the total biomarker market

Clinical Diagnostic Biomarker Market by Disease

In 2020 , growth in the total global market for clinical diagnostic markers has been strong, with strong expansion expected to continue. The report discusses how this growth will be fueled by an aging population that is more susceptible to disease, the increasing number of targeted therapies being developed and introduced, and the large and growing clinical diagnostic test market. Further, analysis in the report of key segments, such as the infectious disease and cancer segments, shows that growth will occur at different rates. The report provides the following data on segments of the clinical diagnostic biomarker market by disease:

  • Total Global Clinical Diagnostic Biomarker Market, 2015-2025, in $Millions (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other, Total)
  • Clinical Diagnostic Biomarker Market Segments, 2015, 2020 , 2025, by Share (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease, Other)

Cancer Biomarker Market

Cancer immunoassays (tumor markers) detect proteins in the blood, urine, or other body fluids such as sputum, breast nipple aspirate, and semen. The presence of these proteins, or their relative levels, may indicate an abnormal process in the body, such as cancer, and can provide further information if cancer is diagnosed. Doctors use tumor marker tests at various stages in patient care: for diagnosis, treatment monitoring and disease recurrence.

The report provides the following cancer biomarker market data:

  • Total Global Clinical Diagnostic Cancer Biomarker Market, 2015-2025 , in $Millions (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Total)
  • Clinical Diagnostic Cancer Biomarker Market Segments, 2015, 2020 , 2025, by Share (%) (Cancer, Cardiovascular Disease, Immunological Disease, Infectious Disease, Neurological Disease)
  • Total Global Clinical Diagnostic Cancer Biomarker Market by Segment, 2015, 2020 , 2025, in $Millions (Histology/Cytology: Immunohistochemistry, In Situ Hybridization; Immunoassays - Tumor Markers: PSA, CEA, CA 125, AFP, Others, Flow Cytometry; Rapid Tests: Fecal Occult Blood, PSA, NMP22, Others; Molecular Assays; Total)

Infectious Disease Biomarker Market

The largest disease segment at this time is infectious diseases. This market includes tests to detect antigens or nucleic acid (DNA or RNA) sequences from microbes, and also markers of the body's response to the infection, such as antibodies produced against a specific pathogen that has infected a person. These are important biomarkers to determine if a person is, or has been, infected. These biomarkers can also sometimes be used to demonstrate the efficacy of treatment. For bacterial infections, antibiotic resistance genes are also important biomarkers to predict which antibiotics are not likely to be effective for treatment of a bacterial infection.

The report provides the following infectious disease biomarker market data:

  • Total Global Clinical Diagnostic Infectious Disease Biomarker Market, 2015-2025, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation, Total)
  • Growth of Global Clinical Diagnostic Infectious Disease Biomarker Market, 2015-2025, in $Millions (Laboratory Immunoassays, Rapid Immunoassays, Molecular Assays)
  • Clinical Diagnostic Infectious Disease Biomarker Market Segments, 2015, 2020 , 2025, by Share (%) (Laboratory Immunoassays, Rapid Immunoassays, Molecular Assays)
  • Total Global Clinical Diagnostic Infectious Disease Biomarker Market by Segment, 2015, 2020 , 2025, in $Millions (Laboratory Immunoassays [Hepatitis; HIV; STDs including chlamydia, gonorrhea and syphilis; TORCH; Respiratory; Sepsis including sepsis markers, C. difficile, MRSA, other AMR/HAI tests; Parasitology; Mycology; Others including EBV, Chagas, dengue, malaria, Lyme disease, others], Rapid Immunoassays [Influenza; HIV; Malaria; Hepatitis; STDs including chlamydia and syphilis; C. difficile; E. coli; Strep A; H. pylori; Others including rapid tests for TB, Dengue, Chagas, vaginitis, Group B Strep and others], Molecular Assays [HAIs; HIV; Hepatitis; Chlamydia/Gonorrhea (CT/NG); HPV; Respiratory; Mycobacteria/TB; Others], Total)

Cardiovascular Disease Biomarker Market

Cardiac biomarkers are substances that are released into the bloodstream when the heart is damaged or stressed. As discussed in the report, cardiovascular disease includes all diseases or disorder of the heart and the vascular system of the body. Many different biomarkers have been identified to help physicians diagnose disease, identify individuals at increased risk of disease, and to monitor certain conditions.

The World Market for Biomarkers provides the following information on the global diagnostic market for cardiovascular disease biomarkers:

  • Total Global Clinical Diagnostic Cardiovascular Disease Biomarker Market, 2015-2025, in $Millions (Cardiac Markers, Cholesterol/Lipids, Coagulation, Total)
  • Clinical Diagnostic Cardiovascular Disease Biomarker Market Segments, 2015, 2020 , 2025, by Share (%) (Cardiac Markers, Cholesterol/Lipids, Coagulation)
  • Total Global Clinical Diagnostic Cardiovascular Disease Biomarker Market by Segment, 2015, 2020 , 2025, in $Millions (Cardiac Markers [Acute Condition Cardiac Markers: CK-MB, myoglobin, brain natriuretic peptide (BNP); cTn; HscTn; Other cardiac markers: proBNP, hsCRP, homocysteine, others], Cholesterol/Lipids, Coagulation [PT/INR-lab, D-dimer, Molecular (Thrombophilia SNPs), POC], Total)

Immunological Disease Biomarker Market

There are many different diseases that involve an abnormal immune response, as discussed in the report. Two immunological disease categories for which diagnostic testing is commonly performed are autoimmune disease and allergy. More than 80 different autoimmune related diseases have been identified. In addition, individuals can develop an allergic response to a wide array of allergens. As a result, these diagnostic markets include a wide range of different biomarkers that can be tested.

The report provides the following information on the sales of biomarkers related to immunological disease:

  • Total Global Clinical Diagnostic Immunological Disease Biomarker Market, 2015-2025, in $Millions (Autoimmune Disease, Allergy, Total)
  • Clinical Diagnostic Immunological Disease Biomarker Market Segments, 2015, 2020 , 2025, by Share (%) (Autoimmune Disease, Allergy)

Neurological Disease Biomarker Market

Neurological diseases are those that affect the central nervous system (brain and spinal cord) and the peripheral nervous system. This group encompasses many age-related diseases such as dementia, neurodegenerative diseases, inherited neurodevelopmental disorders, as well as autoimmune diseases such as multiple sclerosis, diabetic neuropathy, stroke, and many others. Because they are systemic, distinct, complex and generally not as widespread as the illnesses discussed elsewhere in this report, biomarker development in this area has been slower. However, the aging of the population and rapid increase of severe and costly diseases such as Alzheimer's disease has made this area a priority for a rising number of research groups. As such, it is a fast growing biomarker segment of which the report notes total global sales:

  • Total Global Clinical Diagnostic Neurological Disease Biomarker Market, 2015-2025, in $Millions (Autoimmune Disease, Allergy, Total)
  • Clinical Diagnostic Neurological Disease Biomarker Market Segments, 2015, 2020 , 2025, by Share (%) (Alzheimer's Disease, Other Neurological Disorders)

Other Diseases

The "other" segment includes many different types of biomarkers used in diagnostic applications such as bone diseases, renal disease, transplantation, other endocrine diseases, and other varied disease indications. As discussed in the report, a broad definition of biomarkers is used has been used in this report. Biomarkers in this report include molecules or other characteristics that can be measured, and are indicators of a health, risk of disease, disease or other condition, prognosis, response to therapy, or other biological effect. This definition includes biomarkers that are used in drug development as surrogates, markers of drug safety, or other applications. Traditionally, biomarkers have been discussed and evaluated as single molecules or characteristics, and many tests are available for individual biomarkers. The World Market for Biomarkers provides the following information on the sales of biomarkers related to the following segments: general clinical chemistry, fertility/pregnancy, thyroid, diabetes/Hb1Ac, chromosome analysis & inherited disease, and other:

  • Total Global Clinical Diagnostic Other Biomarker Market, 2015-2025, in $Millions (General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other, Total)
  • Clinical Diagnostic Other Biomarker Market Segments, 2015, 2020 , 2025, by Share (%)(General Clinical Chemistry, Fertility/Pregnancy, Thyroid, Diabetes/Hb1Ac, Chromosome Analysis & Inherited Disease, Other)

C-Reactive Protein (CRP)

C-Reactive Protein (CRP) is an important biomarker for several diseases. Due to the high and rising interest in CRP tests, a breakout of estimated sales is provided:

  • Total Global CRP Biomarker Market, 2015-2025, in $Millions

Biomarker Market Drivers and Restraints

For this report, the market for biomarkers focuses on applications of biomarkers. This includes both research and diagnostic applications of biomarkers. The potential market for biomarkers being evaluated as potential drug targets is not included in this market analysis, as that therapeutic market would be determined by the potential market for new therapies targeting the biomarker drug target.

The report examines biomarker market drivers and restraints. As in other markets, a variety of drivers and restraints exert influences to varying degrees. Some of these drivers and restraints operate at a macro level, affecting the entire industry, while others mainly affect certain segments, companies, geographies, or other select situations. The market for a biomarker that is developed and commercialized for diagnostic applications is driven by the market and need for diagnostic assays that detect that biomarker.

Key Technologies Used to Identify & Analyze Biomarkers

Many different technologies have been developed and are used in biomarker discovery, and also for detection and analysis of known biomarkers. These include traditional technologies, some of which have been used for decades. In addition, many new technologies developed for other applications are now being applied in this field. These include mass spectrometry and next generation DNA sequencing. Many tests performed using newer technologies are currently being done primarily as laboratory developed tests (LDTs) or by organizations performing clinical tests for pharmaceutical companies developing new drugs; however, some companies plan to eventually develop IVD test kits based on their laboratory assays.

Selected examples of companies using these various technologies are discussed in this report, including key players in the market:

  • Selected Companies Using Immunoassays for Detection and Analysis of Biomarkers, 2020
  • Selected Companies with Immunohistochemistry Tests for Detection of Biomarkers, 2020
  • Selected Companies Using In Situ Hybridization for Detection and Analysis of Biomarkers, 2020
  • Selected Companies Using PCR or Other Nucleic Acid Amplification-Based Technologies for Biomarker Assays, 2020
  • Selected Companies Analyzing Gene Signatures, 2020
  • Selected Companies Using Microarrays to Detect and Analyze Biomarkers, 2020
  • Selected Diagnostics Companies and Clinical Laboratories with Sequencing-Based Biomarkers, 2020
  • Selected Companies Using Mass Spectrometry, 2020

Competition in the Market

The World Market for Biomarkers includes profiles of companies active in the discovery and/or commercialization of biomarkers. This includes companies commercializing in vitro diagnostic tests for detection and analysis of biomarkers, selected diagnostic companies commercializing diagnostic tests in their own CLIA certified laboratories for detection and analysis of biomarkers, and selected other players. The report's focus is on companies with commercialized products and/or very advanced development programs. The diagnostics market is a highly competitive market, and there are many additional diagnostic companies that offer tests based on biomarkers discussed in this report.

Companies profiled in the report range from large, multinational companies to smaller companies in or entering this market, including the following:

  • 20/20 GeneSystems, Inc.
  • Abacus Diagnostica Oy
  • Abbott Laboratories
  • Act Genomics Co., Ltd.
  • Adaptive Biotechnologies Corp.
  • Admera Health
  • Agena Bioscience Inc.
  • Agendia NV
  • Agilent Technologies, Inc.
  • ALPCO
  • Ambry Genetics Corp.
  • Athena Diagnostics, Inc. /Quest
  • Banyan Biomarkers, Inc.
  • Beckman Coulter, Inc./Danaher Corp.
  • Becton, Dickinson and Company
  • BioFire Diagnostics, LLC/BioMerieux
  • Biohit Oyj
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Cancer Genetics, Inc.
  • Caris Life Sciences
  • Cepheid/Danaher Corp.
  • Curetis AG
  • Exact Sciences Corp.
  • Foundation Medicine, Inc.
  • Fujirebio, Inc.
  • Genomic Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics
  • NeoGenomics
  • Ortho-Clinical Diagnostics
  • Qiagen N.V.
  • Roche
  • Siemens Healthineers
  • Sysmex Corp.
  • Thermo Fisher Scientific, Inc.
  • Ventana Medical Systems, Inc./Roche
  • Zeus Scientific, Inc.

Table of Contents

Chapter 1: Introduction

  • Report Coverage
  • Methodology
  • Sources of Information

Chapter 2: Executive Summary

  • Table 2-1: Summary Table: Global Biomarker Sales by Product Group & Region (million dollars), 2018-2027 (Product Groups: Infectious Diseases, Cancer, Cardiovascular, Clinical Chemistry, Neurological, Autoimmune, and Other & Regions: North America, Western Europe, Asia/Pacific, Central & South America, Eastern Europe, Middle East, and Africa)

Chapter 3: Market Environment & Analysis

  • Overview
  • Demographic Patterns
    • World Healthcare Trends
      • Table 3-1: Global Demographic & Healthcare Indicators, 2018-2027 (World Population, Healthcare Expenditures, Healthcare Resources, and Healthcare Activity)
  • Biomarker Technologies
  • Biomarker Market Analysis
    • Biomarker Products
      • Table 3-2: Global Biomarker Sales by Product Group (million dollars), 2018-2027 (Infectious, Cancer, Cardiovascular, Clinical Chemistry, Neurological, Autoimmune, and Other)
      • Figure 3-1: 2020 Global Biomarker Product Sales by Type ) ($43.0 million), (Infectious, Cancer, Cardiovascular, Clinical Chemistry, Neurological, Autoimmune, and Other
    • Geographical Markets
      • Table 3-3: Global Infectious Disease Biomarker Sales by Region (million dollars), 2018-2027 (U.S., Canada, Mexico, Asia Pacific, China, Japan, Western Europe, Eastern Europe, Central America, South America, and Africa and the Middle East)
      • Figure 3-2: Biomarker Product Sales by Major Geographical Market, 2020 ($43.04 billion), (U.S., Canada, Mexico, Asia Pacific, China, Japan, Western Europe, Eastern Europe, Central America, South America, and Africa and the Middle East)

Chapter 4: Infectious Disease Biomarkers

  • Overview
    • Table 4-1: Global Infectious Disease Biomarker Sales by Major Product Group (million dollars), 2018-2027 (Respiratory, HAIs, Hepatitis, HIV, STDs, TORCH, and Other)
  • Infectious Disease Biomarker Technologies
    • Table 4-2: Global Infectious Disease Biomarker Sales by Technology (million dollars), 2018-2027 (Lab Immunoassay Tests, Molecular Tests, and Rapid Immunoassay Tests)
  • COVID-19 Biomarkers
    • Table 4-3: COVID-19 Tests by Type, 2020 and 2021, (millions) (Molecular, Antigen, and Antibody)
    • Table 4-4: Global COVID-19 Test Sales by Type, 2020 and 2021 (million dollars) (Molecular, Antigen, and Antibody)
    • Table 4-5: Major COVID-19 Test Vendors by Category, unranked
  • Respiratory Diseases
    • Table 4-6: Global Respiratory Disease Biomarker Sales by Condition (million dollars), 2018-2027 (Pneumonia, Influenza, Group Strep A, Tuberculosis, and Other)
    • Figure 4-1: Respiratory Disease Biomarker Product Sales Breakdown by Condition, 2020 (Pneumonia, Influenza, Strep A, Tuberculosis, and Other)
    • Table 4-7: Global Respiratory Disease Biomarker Sales by Technology (million dollars), 2018-2027 (Laboratory Immunoassay, Molecular, and POC)
    • Pneumonia
    • Influenza
    • Group A Streptococcus Infections
    • Tuberculosis
    • Other Respiratory Infections
  • Healthcare-Associated Infections (HAIs)
    • Table 4-8: Global Healthcare-Associated Infections (HAIs) Biomarker Sales by Type (million dollars), 2018-2027 (C. diff, Sepsis, Staph, Enterococci, and Other)
    • Clostridioides difficile (c. diff)
    • Sepsis
    • Staphylococcus aureus
    • Enterococcus
    • Other Healthcare-Associated Infections
  • Hepatitis
    • Types of Hepatitis
    • Hepatitis Biomarkers
      • Table 4-9: Global Hepatitis Biomarker Sales by Type (million dollars), 2018-2027 (Hepatitis B, Hepatitis C, and Other Types)
    • Commercial Hepatitis Tests
  • HIV
    • Overview
    • Statistical Trends
    • Biomarker-Based HIV Tests
      • Table 4-10: Global HIV Biomarker Sales by Technology (million dollars), 2018-2027 (Immunoassay, Molecular, and Rapid POC)
    • Commercial HIV Tests
  • Sexually Transmitted Diseases (STDs)
    • Table 4-11: Global STD Biomarker Sales by Type (million dollars), 2018-2027 (HPV, CT/NG, Trichomoniasis, HSV 1&2, and Other)
    • Human Papillomavirus (HPV)
    • Chlamydia/Gonorrhea (CT/NG)
    • Trichomoniasis
    • Herpes Simplex Virus (HSV-1 & HSV-2)
      • Table 4-12: Producers of Herpes Simplex Virus Tests
    • Other Sexually Transmitted Diseases
  • TORCH
    • Table 4-13: Global TORCH Biomarker Sales (million dollars), 2018-2027
  • Other Infectious Diseases
    • Table 4-14: Global Other Infectious Disease Biomarker Sales by Type (million dollars), 2018-2027 (Malaria, Lyme Disease, E. Coli, H. pylori, Dengue, and All Other)
    • Malaria
    • Lyme Disease
    • coli
    • pylori
    • Dengue
    • All Other Disease

Chapter 5: Cancer Biomarkers

  • Overview
  • Types of Cancer Biomarkers
    • Table 5-1: Global Cancer Biomarker Sales by Type (million dollars), 2018-2027 (CTMs and TTMs)
  • Market Analysis
    • Table 5-2: Global Cancer Biomarker Sales by Condition (million dollars), 2018-2027 (Breast, Prostate, Lung, Colorectal, Melanoma, Bladder, Uterine, Non-Hodgkin Lymphoma, Kidney, Leukemias, Pancreatic, Thyroid, Liver, Multiple Myeloma, Stomach, Ovarian, Esophageal, and All Other)
  • Biomarker Product Suppliers

Chapter 6: Cardiovascular Biomarkers

  • Overview
  • Key Biomarkers
  • Market Analysis
    • Table 6-1: Global Cardiovascular Biomarker Sales by Product Group (million dollars), 2018-2027 (Coagulation, CAD, CHF, MI, Cerebrovascular, Atherosclerosis, Cholesterol/Lipid, and Other)
  • Biomarker Product Suppliers

Chapter 7: Clinical Chemistry Biomarkers

  • Overview
  • Blood Gases & Electrolytes
  • Urinanalysis
  • Workstation Immunoassay Tests
  • Market Analysis
    • Table 7-1: Global Clinical Chemistry Biomarker Sales by Product Group (million dollars), 2018-2027 (Glucose, Electrolytes, Cardiac Biomarkers, Enzymes, HbA1c, Proteins, Drugs of Abuse, Therapeutic Drugs, and Other)
  • Biomarker Product Suppliers

Chapter 8: Neurological Biomarkers

  • Overview
  • Key Biomarkers
  • Market Analysis
    • Table 8-1: Global Neurological Biomarker Sales by Product Group (million dollars), 2018-2027 (Alzheimer's Disease, Neuropathy Disorders, Epilepsy, Parkinson's Disease, Multiple Sclerosis, and Other)
  • Biomarker Product Suppliers

Chapter 9: Autoimmune Biomarkers

  • Overview
  • Key Biomarkers
  • Market Analysis
    • Table 9-1: Global Autoimmune Biomarker Sales by Product Group (million dollars), 2018-2027 (Hashimoto's Thyroiditis, Rheumatoid Arthritis, Type 1 Diabetes, Celiac Disease, Ulcerative Colitis, SLE, Crohn's Disease, and Other)
  • Biomarker Product Suppliers

Chapter 10: Other Biomarkers

  • Overview
    • Table 10-1: Other Global Biomarker Sales by Product Group (million dollars), 2018-2027 (Diabetes & Metabolic, Fertility & Pregnancy, Kidney Disorders, Inherited Diseases, Thyroid Conditions, and All Other)
  • Diabetes & Metabolic Biomarkers
  • Fertility & Pregnancy Biomarkers
  • Kidney Disorders
  • Inherited Diseases
    • Cystic Fibrosis
    • Down Syndrome
    • Sickle Cell Disease
    • Gaucher Disease
    • Familial Hypercholesterolemia
    • Muscular Dystrophy
    • Hemophilia
    • Von Willebrand Disease
    • Neurofibromatosis
    • Polycystic Kidney Disease
    • Spinal Muscle Atrophy
    • Klinefelter Syndrome
    • Canavan disease
    • Cerebral Palsy
    • Angelman Syndrome (AS)
    • Other Inherited Diseases
  • Thyroid Conditions
  • All Other Biomarkers
    • Bone Disease Biomarkers
    • Gastrointestinal Biomarkers
    • Respiratory Biomarkers

Chapter 11: Company Profiles

  • Table 11-1: IVD Biomarker-Related Sales of Selected Industry Leaders, 2020 (million dollars) (Roche Diagnostics, Abbott Diagnostics, Danaher, Thermo Fisher Scientific, Siemens Healthineers, Becton Dickinson, bioMérieux, Illumina, Ortho Clinical Diagnostics, Quidel, Exact Sciences, Bio-Rad Laboratories, DiaSorin Group, Myriad Genetics, and Luminex)
    • Roche Diagnostics (Basel, Switzerland)
    • Molecular Testing
    • Companion Diagnostics
    • Circulating Tumor Cells
  • Abbott Diagnostics (Abbott Park, Illinois)
    • COVID-19
    • Point-of-Care Tests
    • Core Laboratory
    • Molecular Assays
    • Companion Diagnostics
    • Liquid Biopsy
  • Danaher Corporation (Washington, D.C.)
    • Cepheid
    • Radiometer
    • Beckman Coulter
    • Leica Biosystems
  • Thermo Fisher Scientific (Waltham, Massachusetts)
  • Siemens Healthineers (Malvern, Pennsylvania)
  • Becton Dickinson, and Company - BD (Franklin Lakes, New Jersey)
  • bioMérieux (Marcy l'Etoile, France)
  • Illumina (San Diego, California)
  • Ortho Clinical Diagnostics (Raritan, New Jersey)
  • Quidel Corporation (San Diego, California)
  • Exact Sciences (Madison, Wisconsin)
  • Bio-Rad Laboratories (Hercules, California)
  • DiaSorin Group (Saluggia, Italy)
  • Myriad Genetics (Salt Lake City, Utah)
  • Luminex Corporation (Austin, Texas)